Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Evidence: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint

Computable Name:

version: 3; Last updated: 2026-08-06 09:26:00+0000

ArtifactPublicationStatus: Active

url: https://fevir.net/resources/Evidence/6512

identifier: FEvIR Object Identifier/6512

name: OSFPreprint_PrimaryOutcomeMeasure_0_OutcomeAnalysis_0_BetweenGroupAnalysis_OG000_OG001

title: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint

citeAs:

Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 6512. Revised 2021-07-19. Available at: https://fevir.net/resources/Evidence/6512. Computable resource at: https://fevir.net/resources/Evidence/6512#json.

status: Active

date: 2021-07-19 21:20:42+0000

author: Brian S. Alper:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

variableDefinition

description:

Adult symptomatic patients with mild COVID-19 were recruited between May and August 2020 from King Abdulaziz University Hospital in Jeddah, Saudi Arabia.

variableRole: Population

observed: Group NCT04401202_Enrollment_Group

intended: NCT04401202 Eligibility Criteria

variableDefinition

description:

Nigella Sativa Oil (NSO)

variableRole: Exposure

observed: supplementation with oral capsules of NSO (MARNYS® Cuminmar 500 mg twice daily for 10 days) plus standard of care

variableDefinition

description:

Control

variableRole: Exposure

observed: standard of care medications alone

variableDefinition

description:

proportion of patients recovered (free of symptoms for 3 days) within 14 days after randomization

variableRole: Outcome

observed: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization

statistic

description:

There were 47 patients in the treatment group (NSO) and 47 patients in the control group. The proportion of patients recovered in the treatment group was significantly higher than the control group, 37 (79%) versus 21 (45%) (p=0.001).

numberAffected: 58

SampleSizes

-NumberOfStudiesKnownDataCount
*194

AttributeEstimates

-TypeQuantity
*P-value0.001